Eli Lilly partners at CRUK tackle the first human study of a new p53-targeted cancer drug
Cancer Research UK has kicked off an early-stage study of a new Eli Lilly cancer drug that will try to hit the ever-elusive target of solid tumors with high levels of p53 mutations.
Investigators at CRUK will start out with a dose-escalation study of the Cdc7 inhibitor to try and find the right balance between safety and efficacy, and then step it up to look at the effect the drug has on several cancers with high levels of p53 mutations. Researchers will start with metastatic bowel cancer, squamous non-small cell lung cancer and high grade serous ovarian cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
